These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15269785)

  • 21. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
    Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.
    Zhao H; Sun G; Kong D; Zhang Y; Shi W; Zhao M; Hong L; Qiao Z
    Med Oncol; 2015 Mar; 32(3):79. PubMed ID: 25698531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
    Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
    Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
    Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
    Bajorin DF; Halabi S; Small E
    Clin Genitourin Cancer; 2009 Oct; 7(3):E66-70. PubMed ID: 19815484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
    Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
    Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
    Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic trioxide: an emerging therapy for multiple myeloma.
    Munshi NC
    Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
    Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
    Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E; Hofmann WK; Nowak D
    Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 37. A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer.
    Huilgol NG
    Int J Hyperthermia; 2006 Aug; 22(5):391-7. PubMed ID: 16891241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.